CD4 and neoplasm: Furthermore, during the treatment, the populations of effector Tregs marked by CD4+CD45RA−FoxP3high reduced, and CD8+ T cells in tumor-infiltrating lymphocytes (TILs) augmented (NCT02476123) [313].